Нyperprolactinemia correction in the complex treatment of endometrial hyperplasia
DOI:
https://doi.org/10.18370/2309-4117.2013.10.7-13Keywords:
endometrial hyperplasia, prolactin, functional hyperprolactinemia, luteal phase defect, hyperestrogenemiaAbstract
The paper describes the results of the research of hormonal changes in women of late reproductive age with nonatypical endometrial hyperplasia combined with functional hyperprolactinemia. The rationale of complex approach to the treatment of such patients with the use of herbal dophaminergic medication Cyclodynon is substantiated.References
Zaporozhan VN Timely diagnostics and treatment of endometrial hyperplastic processes / VN Zaporozhan, TF Tatarchuk, VG Dubinina, NV Cossey // ReproductiveEndocrinology. – 2012. – № 1 (3). – P .5–12.
Kuzmina IY Di erentiated approach to the choice of treatment strategy in patients with endometrial hyperplasia / IY Kuzmina, NM Pasieshvili, ON Pascenco et al. // International Journal of Medicine. – 2011. – № 4. – P. 61–64.
Lacey J Endometrial hyperplasia and the risk of progression to carcinoma / J. Lacey, V. Chia
Maturitas / Expert Review of Anticancer Therapy – May 2009. – V. 63, Is. 1. – P. – 39-44.
Sidorova IS Modern approach to the problem of hyperplastic processes in the endometrium / IS Sidorova, NA Sheshukova, AS Fedotova // Russian Journal of the ObstetricianGynecologist. – 2008. – . 5. – P. 19–22.
Marsden DE, Hacker NF Optimal management of endometrial hyperplasia. Best Practice and Research / D.E. Marsden, N.F. Hacker// Clin Obstet and Gynec. – 2001. – № 15 (3). – С. 393–405.
Gasparyan ND, Kareva EN, Gorenkova OS et al. Optimization of anti-recurrent hormonal therapy of hyperplastic processes in the endometrium in women of late reproductive age // Russian Journal of the Obstetrician-Gynecologist. – 2007. – № 5. – P. 31–35.
Gasparyan ND, Kareva EN, Gorenkova OS et al. Optimization of anti-recurrent hormonal therapy of hyperplastic processes in the endometrium in women of late reproductive age // Russian Journal of the Obstetrician-Gynecologist. – 2007. – № 5. – P. 31–35.
Tkachenko LV Current views on the pathogenesis of endometrial hyperplastic processes in menopausal women / LV Tkachenko, NI Sviridova // Heraldof VOLGGMU. – 2007. – P. 3–7.
Adamyan LV, Glyakin DS, Samoilova AV et al. In ammatory process in the etiology and pathogenesis of endometrial cancer // Reproduction Problems. – 2007. – № 1. – P. 21–25.
Burlev VA, Sarkisov SE, Ilyasova NA et al. Eutopic endometrial hyperplasia: atypia and angiogenesis // Reproduction Problems. – 2007. – № 5. – P. 21–27.
Tatarchuk TF Issue of the treatment of endometrial hyperplasia / TF Tatarchuk, LV Kalugina // Reproductive Endocrinology. – 2012. – № 2 (4). – P. 88–92.
Kuznetsova IV Treatment options for endometrial hyperplastic processes / IV Kuznetsova // Journal «Di¡ cultPatient.» – 2010. – № 1–2.
Cossey NV New aspects of the biological role of systemic and local hyperprolactinemia / NV Cossey, TN Tutchenko, LA Vasil’chenko // Reproductive Endocrinology. – 2012. – № 4 (6). – P. 8–13
Tatarchuk TF Modern approaches to the diagnostics and treatment of hyperprolactinemia / TF Tatarchuk, SV Gunkov, OA Efymenko // Reproductive Endocrinology. – 2012. – № 1 (3). – P. 44.
Egli M Prolactin secretion patterns: basic mechanisms and clinical implications for reproduction / M Egli, B Leeners, THC Kruger // Reproduction. – 2010. – Vol. 140. – P. 643–654.
Levina V Biological signi£ cance of prolactin in gynecologic cancers / V Levina, B Nolen, Yunyun Su et al. // Cancer Res. – 2009. – Vol. 69 (12).
Berinder K Cancer risk in hyperprolactinemia patients: a population-based cohort study / K Berinder, O Akre, F Granath et al. // Endocrinol. – 2011. – Vol. 1. – Р. 209–215.
Bernichtein S New concepts in prolactin biology / S Bernichtein, Ph Touraine, V Go¡ n // Journal of Endocrinology. – 2010. – Vol. 206. – Р. 1–11.
Ignacak M, Kasztelnik T, Sliwa RA, Korbut K, Rajda TJ Guzik рrolactin – not only lactotrophin a «new» view of the «old» hormone / M Ignacak, T Kasztelnik, R Sliwa et. аl. / Journal of physiology and pharmacology. – 2012. – Vol. (63). – Р. 435–443.
Grattan DR Prolactine: A pleirotropicneuroendsocrine hormone / DR Grattan, IC Kokay // Journal of Neuroendocrinology. – 2008. – Vol. 20. – P. 752–763.
Nowak RA Prolactin is an autocrine or paracrine growth factor for human myometrial and leiomyoma cells / Nowak RA, Mora S, Diehl T еt al. // Gynecolobstetinvest. – 1999. – Vol. 48. – P. 127–132.
Baban RS Prolactin receptors in uterine leiomyomas / RS Baban, ST Al-Zuheiri, YY Farid // Saudi Med J. – 2008. – Vol. 29, № 11. – P. 1593–1596.
Sabry M Innovative oral treatments of uterine leiomyoma / M Sabry, A Al-Hendy // Obstetrics and gynecology international. – Vol. 2012. – P. 1–10.
Selmano IR Hyperprolactinemia alters the frequency and amplitude of pulsatile luteinizing hormone secretion in the ovariectomized rat cohen-becker / IR Selmano , PM Wise // Neuroendocrinology. – 1986. – Vol. 42. – P. 328–333.
Serri O The in uences of hyperprolactinemia and obesity on cardiovascular risk markers: e ects of cabergoline therapy / O Serri, L Li, J Mamputu // Clinical Endocrinology. – Vol. 64 (4). – 2006. – P. 366–370.
Brandebourg T, Hugo E, Ben-Jonathan N Adipocyte prolactin: regulation of release and putative functions / T Brandebourg, E Hugo, N Ben-Jonathan // Diabetes obesmetab. – 2007. – Jul; 9 (4). – P. 464–76.
Arkhipkina TL Prolactin role in the formation of carbohydrate metabolism in patients with polycystic ovary syndrome / TL Arkhipkina, LP Lyubimova, EI Kalenik // Problemsof the endocrine pathology. – 2010. – № 1. – P. 38–44.
Tatarchuk TF Treatment of the stress-induced luteal phase de£ ciency / TF Tatarchuk, NV Cossey, TN Tutchenko // Reproductive Endocrynology. – 2011. – № 2. – P. 34–39.
Marsden DE Optimal management of endometrial hyperplasia. Best Practice and Research / DE Marsden, NF Hacker // Clin. Obstet. and Gynec. – 2001. – Vol. 15. – P 393–405.
Downloads
Published
Issue
Section
License
Copyright (c) 2014 Т. Ф Татарчук, Т. Н. Тутченко
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
